Active immunization with fibrillar β-amyloid peptide (Aβ 42 ) as well as passive transfer of anti-Aβ antibodies significantly reduces Aβ plaque deposition, neuritic dystrophy, and astrogliosis in the brain of mutant amyloid precursor protein (APP)-transgenic mice. Although the mechanism(s) of clearance of Aβ from the brain following active or passive immunization remains to be determined, it is clear that anti-Aβ antibodies are critical for clearance. DNA immunization provides an attractive alternative to direct peptide and adjuvant approaches for inducing a humoral response to Aβ. We constructed a DNA minigene with Aβ fused to mouse interleukin-4 (pAβ 42 -IL-4) as a molecular adjuvant to generate anti-Aβ antibodies and enhance the Th2-type of immune responses. Gene gun immunizations induced primarily IgG1 and IgG2b anti-Aβ antibodies. Fine epitope analysis with overlapping peptides of the Aβ 42 sequence identified the 1-15 region as a dominant B cell epitope. The DNA minigeneinduced anti-Aβ antibodies bound to Aβ plaques in brain tissue from an Alzheimer's disease patient demonstrating functional activity of the antibodies and the potential for therapeutic efficacy.
Introduction
Alzheimer's disease (AD) is the most common form of dementia in the elderly and is characterized by a progressive loss of memory and a general cognitive decline. The neuropathological features of the disease include neurofibrillary tangles, deposition of β-amyloid peptides (Aβ 40 or Aβ 42 ) in plaques, and neuronal loss in affected brain regions [1] . The Aβ peptides cleaved from the amyloid precursor protein (APP) by the β-and γ-secretases [2] [3] [4] [5] are believed to play a central role in the onset and progression of AD [6] . Recently, Schenk et al. [7] demonstrated that immunization of APP-transgenic (APP/Tg) mice with Aβ 42 induced the generation of antibodies, which dramatically reduced the deposition of amyloid plaques and promoted the clearance of plaques from the brain. Other groups have reported similar observations and have extended these studies by showing that active immunization protected mice from developing functional memory deficits [8] [9] [10] . Remarkably, passive administration of an anti-Aβ monoclonal antibody to APP/Tg mice also resulted in decreased Aβ levels in the brain, significantly reducing the AD-like neuropathology [11, 12] , and reversing memory deficits [13] . These results suggest that the generation of antibodies against Aβ in humans might provide protection against the onset of AD [14] .
Based on these data, Aβ immunotherapy has been moved to the clinical trials. The AN1792 vaccine was comprised of Aβ 42 as the antigen and QS21 as the adjuvant. Unfortunately, the vaccine trial was halted because approximately 5% of the participants receiving the vaccine developed some degree of meningoencephalitis [14, 15] . The failure of this clinical trial is disappointing; however, this does not mean that other Aβ immunotherapy strategies will not eventually be successful in treating AD. Because Th1-mediated responses have been implicated in many autoimmune diseases [16] , there has been speculation that the adjuvant may have contributed to the adverse response in a subset of the patients receiving the AN1792 vaccine [17, 18] . Alternative, immunotherapy approaches that polarize the immune response to Aβ towards a Th2 phenotype, that in some cases have been shown to inhibit autoimmune diseases, may provide significant advantages [19, 20, 21] . An example of this type of approach is the intranasal immunization of APP/Tg mice with Aβ 42 but without a conventional adjuvant, which was shown to induce a Th2-mediated humoral response to Aβ [18, 22] .
Another adjuvant-free vaccination approach is DNA immunization, which has been shown to generate potent humoral and cellular immune responses against viral, tumor, and foreign antigens [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Importantly, it has also been reported that co-administration of IL-4 cytokine gene along with a gene, encoding foreign or "self" antigens, caused the immune response to be driven toward a more Th2-like phenotype [20, 21, [35] [36] [37] [38] [39] . Here we describe a novel chimeric DNA minigene encoding Aβ fused with mouse IL-4. Immunization of wild-type mice with the pAβ 42 -IL-4 generated a potent humoral response to Aβ. Analysis of the IgG isotypes showed that IgG1 and IgG2b were the predominant species, which suggests that the immune response was primarily Th2-mediated. The anti-Aβ antibodies generated were specific for the Nterminal region of Aβ 42 and recognized Aβ plaques in human AD brain tissue, which indicated that antibodies are potentially therapeutic.
Results

Expression of chimeric DNA minigenes in vitro
Three different plasmids were constructed (Fig. 1a, b) , and expression of all plasmids has been confirmed by analyzing the lysate and supernatants of transiently transfected Chinese hamster ovary (CHO) cells (Fig. 1c-e) . The additional bands in the region between 19-24 kDa (lanes 1-2) likely represent different glycosylation states [40] of Aβ 42 -IL-4 or Aβ 28 -IL-4 fusion proteins. Importantly, we did not detect any Aβ peptides in the supernatant or lysate of cells transfected with vector DNA (Fig. 1c, lane 2 , and data not shown). In addition to Western blot (WB), the expression of Aβ 42 , Aβ 42 -IL-4, and Aβ 28 -IL-4 were confirmed by flow cytometry analysis using immunostaining with monoclonal anti-Aβ 42 6E10 and anti-IL-4 antibodies (Fig.  1f-h ). Transiently transfected CHO cells expressed Aβ 42 , Aβ 42 -IL-4 and Aβ 28 -IL-4 molecules.
Generation of anti-Aβ antibodies
We immunized B6SJLF1 mice by bombardment of the skin with microscopic gold particles coated with the various DNA minigenes using the Helios gene gun. Mice immunized with pAβ 42 did not generate anti-Aβ 42 antibodies (data not shown). In contrast, conjugation of Aβ 42 with IL-4 resulted in a robust anti-Aβ 42 immune response generated by three out of eight experimental mice after only two boosts. Anti-Aβ 42 antibody responses in three mice were moderate, whereas the remaining two mice responded weakly (Fig. 2a) . Antibody titers of the pooled sera were detected in two separate experiments and were equal to 1:3,200 (Fig. 2b ). Mice immunized with vector did not induce anti-Aβ 42 antibody production, whereas injection of psHA-mC3d 3 generated only antihemagglutinin (HA)-specific antibodies (data not shown). Thus, the presence of the mouse IL-4 molecular adjuvant in the plasmid was critical for generation of anti-Aβ specific antibody responses.
There is a high level of homology between human and rodent Aβ 42 peptides [41] . Accordingly, we demonstrated that immunization with pAβ 42 -IL-4 that encodes human Aβ 42 induces crossreactivity with mouse Aβ 42 . However, the antisera bound to rodent Aβ 42 two times weaker than to human Aβ 42 (data not shown). Because we demonstrated the immune response to the self-Aβ 42 peptide, it was also interesting to analyze antibody production to the self-IL-4 molecule. Our data indicate that DNA vaccination with pAβ 42 -IL-4 generated low-titer antibodies to the IL-4 molecular adjuvant (Fig. 3 ).
Characterization of anti-Aβ 42 antibodies by isotyping
We analyzed isotypes of anti-Aβ 42 antibodies in the sera of six mice, which represent high and moderate responders. All animals generated IgG1 antibodies, whereas the level of IgG2a b was negligible. The production of IgG1 antibodies is an indirect measure of the relative contribution of Th2-type cytokines, whereas IgG2a antibodies reflect the contribution of Th1 to the immune response [32] . Thus our data indicate that pAβ 42 -IL-4 minigene induces a highly Th2-polarized response. Four mice with the highest production of IgG1 antibodies also generated significant levels of IgG2b (Fig. 4) . There was no IgE or IgA antibody production detected in immunized mice (data not shown).
Mapping of B cell epitopes and binding to human β-amyloid plaques
In order to identify epitopes recognized by antibodies induced after DNA immunization, we analyzed binding of immune sera to the six overlapping peptides by competition ELISA. Preincubation of sera from high and moderate responders with the full-length Aβ 42 peptide resulted in the most complete inhibition of antibody binding to the adsorbed Aβ 42 peptide (82-98% inhibition). The peptide Aβ 1-15 was also effective, inhibiting the binding of antisera by 49-92%. In addition, Aβ [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] showed partial inhibition of antibody binding. Notably, a mixture of Aβ [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , Aβ [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and Aβ 26-42 peptides (2.5 μM each) was ineffective (Fig. 5 ).
To analyze the capability of these antibodies to bind to Aβ plaques in human brain tissue, we used pooled sera from six immunized mice. This antiserum bound to Aβ plaques on the brain sections of cortical tissue from a severe AD case (Fig. 6 ). The antisera were effective at a dilution of 1:1,000, the endpoint dilution used in these experiments. The pre-immune sera from these mice did not bind to the Aβ plaques. Notably, Aβ 42 peptide abrogated binding of antisera to the Aβ plaques in human brain tissue (Fig. 6 ).
To examine inflammation-related pathology in the brain of animals immunized with DNA minigene, we conducted immunohistochemical analysis. To identify microglia activation as well as leukocyte infiltration and accumulation in the brain, we analyzed expression of CD45, CD11b, CD4, CD8, and CD54 molecules. As shown in Fig. 7 , immunostaining in sections from the frontoparietal cortex revealed no observable differences between wild-type and immunized mice. CD11b-positive microglial cells exhibited a resting morphology with long fine processes. Importantly, CD4-positive cells were found within blood vessels but had not infiltrated into the neuropil.
Discussion
The development of a safe and effective vaccine requires a delicate balance between providing a specific and adequate immune response to provide protection, and reducing or eliminating unwanted adverse events that may induce excess inflammation or an autoimmune response. While there are significant safety concerns about Aβ immunotherapy as a possible treatment for AD, there is also considerable optimism that these hurdles can be overcome with other vaccination approaches. Alternative strategies have been suggested, such as using different adjuvants, different routes of immunization and the using molecular adjuvant(s), such as cytokines in conjunction with Aβ-based vaccine to drive the Th phenotype toward the desired pathway [18, 19, 22, 42] . In this study we have employed a chimeric DNA minigene to deliver a fusion protein containing Aβ antigen together with IL-4 as a molecular adjuvant to amplify immune response to Aβ and to further polarize the response toward a Th2 phenotype in vivo.
Thirteen years ago, it was demonstrated that a gene could be transferred in situ by inoculation of a plasmid vector into muscle [43] . Now, the generation of potent humoral and cellular immune responses to a broad spectrum of pathogen antigens has been demonstrated in different animal model systems using DNA vaccination [25] [26] [27] [28] [29] [30] 34, [44] [45] [46] [47] [48] [49] . DNA immunization offers significant advantages over peptide/protein-based immunization. First it offers the capability to modify genes encoding desired antigen(s), to change the cellular localization of an antigen by adding or removing signal sequences or transmembrane domains, and to target the desired type of immune response using the appropriate molecular adjuvants. Previously we used these approaches to generate potent humoral and cellular immune responses against different antigens [25] [26] [27] [28] 45, 50] . Now to generate potent antibody production to Aβ antigen we prepared plasmids, encoding antigen (Aβ 42 or Aβ 28 ) fused with IL-4 ( Fig. 1) . We demonstrated that mice immunized with pAβ 42 did not generate anti-Aβ 42 antibodies even after six boosts (data not shown), whereas plasmids, encoding immunogen and IL-4 induced anti-Aβ 42 antibodies after just two boosts (Fig. 2 ).
We and others have previously mapped B cell epitopes using antisera from mice immunized with fibrillar Aβ 42 and small peptides derived from Aβ 42 [11, 19, 22, 51, 52] . These results have been confirmed and the linear Aβ 42 epitope spanning residues 4-10 was identified using highresolution mass-spectrometry technique [53] . In this report we demonstrated that antibodies generated after pAβ 42 -IL-4 immunization also recognized Aβ 1-15 peptide. Binding to peptide Aβ 6-20 was detectable, but significantly weaker than binding to Aβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and Aβ 42 (Fig. 5) . Thus, like fibrillar Aβ 42 formulated in different adjuvants [11, 19, 22, [51] [52] [53] [54] , DNA immunization induced antibodies against linear epitope(s) of Aβ 42 that span the N-terminal amino acids of this peptide. Collectively these data suggest that Aβ 1-15 represents the major B cell antigenic determinant of Aβ 42 regardless of DNA or protein immunizations. Interestingly, binding of antibodies to this region of Aβ 42 coincides with the ability of antibodies to bind native plaques in brain tissue [11, 53] and trigger ex vivo phagocytosis [54] . Antibodies generated after gene gun immunization with pAβ 42 -IL-4 also recognize human Aβ plaques in cortical tissues from a severe AD case (Fig. 6 ).
Successful DNA immunization with IL-4 as a molecular adjuvant to enhance Th2 type of immune responses to different immunogens has been previously reported [20, 21, [35] [36] [37] [38] [39] . However, to our knowledge no one examined whether anti-IL-4 antibody production is generated when IL-4 is used as a fusion protein with the immunogen. In this report we have demonstrated that mice immunized with pAβ 42 -IL-4 induced low levels of antibodies to self-IL-4 cytokine (Fig. 3) . Such a response was not unexpected since gene therapy is used to induce immunological memory against self proinflammatory chemokines [55] . IL-4 cytokine is an antiinflammatory cytokine with pleiotropic effects on immune cells of multiple lineages. Thus, production of antibodies to IL-4, unnaturally expressed after DNA vaccination, may be an important regulatory mechanism that protects an organism from overexpression of this cytokine.
The antibody isotype has been used as an indirect measure of the contribution of Th1 and Th2 cytokines to the humoral response [56] . We recently demonstrated that B6SJLF1 mice produce IgG2a b anti-Aβ 42 antibodies instead of IgG2a [57] . Accordingly, we analyzed the IgG1 and IgG2a b profiles of the humoral immune response after DNA immunization. Injections with pAβ 42 -IL-4 induced predominantly IgG1 and to a lesser extent IgG2b anti-Aβ 42 antibodies. Anti-Aβ 42 antibodies of IgG2a b isotype were negligible (Fig. 4) . Thus, the IgG1/ IgG2a ratio measured following immunization with our chimeric Aβ 42 -IL-4 minigene implies that a highly polarized Th2-mediated immune response was generated. More importantly, IgG1 and IgG2b isotypes of anti-Aβ 42 antibodies may correlate with their therapeutic potential [11, 13, 53, 58] . The antibodies generated after Aβ 42 -IL-4 minigene immunization are predominantly of the IgG1 isotype and bound to the first 15 amino acids of Aβ 42 and to Aβ plaques in the AD brain tissue. Therefore, DNA immunization with minigene encoding Aβ antigen and IL-4 molecular adjuvant induces therapeutically potent antibodies to Aβ 42 .
Because T lymphocyte-mediated meningoencephalitis was observed in some patients after immunization with Aβ 42 [59] , we analyzed lymphocyte infiltration into brains of immunized wild-type mice. Immunohistochemical analysis of brain sections did not reveal lymphocytemediated neuroinflammation or microglia activation (Fig. 7) . Because antibodies raised against human Aβ 42 also recognize rodent Aβ 42 , and therefore rodent APP, we speculate that pathological hallmarks in this case may be similar to the ones appearing after vaccination with self-antigen. Future studies with APP/Tg mice immunized with different pAβ-IL-4 constructs are underway and these experiments will better define the therapeutic effects, such as reducing the deposition of Aβ plaques, clearance of plaques from the brain, and protection of mice from developing functional memory deficits, following DNA vaccination.
Materials and methods
Mice
Eight-or ten-week-old female B6SJLF1 mice were purchased from Jackson Laboratories (Bar Harbor, ME) and housed in the animal facility at the Institute for Brain Aging and Dementia, University of California, Irvine (UCI), CA. All animals were housed in a temperature-and light-cyclecontrolled facility and their care was under the guidelines of the National Institutes of Health and the Institute for Brain Aging and Dementia at UCI.
DNA constructs
Three different plasmids encoding secreted forms of Aβ peptide were constructed: pAβ 42 , encoding Aβ 42 ; pAβ 28 -IL-4 and pAβ 42 -IL-4, encoding chimeric proteins, where mouse IL-4 is fused with human Aβ 28 or Aβ 42 , respectively (Fig. 1a, b) . The pAβ 42 was constructed by cloning Aβ 42 PCR fragment into pVAC (Invivogen, San Diego, CA) expression vector in frame with IL-2 signal sequence using BamHI and NheI restriction sites. pAβ 42 -IL-4 and pAβ were constructed by fusion of Aβ 42 or Aβ 28 with IL-4 gene via overlapping PCR techniques using appropriate primers and then cloning into pVAC expression vector using the same restriction sites (IL-2 signal sequence was replaced by IL-4 signal sequence). The correct sequences of the generated plasmids were confirmed by nucleotide sequence analysis. The structure of plasmid psHA-mC3d 3 encoding HA of influenza and three copies of C3d component of complement was described earlier [28] . All plasmids have been purified by Endofree plasmid maxi kit (Qiagen, Valencia, CA). Purity of the DNA was confirmed by UV spectrophotometry (260 nm/280 nm absorbance ratio >1.7) and gel electrophoresis. by psAβ 42 , pAβ 28 -IL-4 and pAβ 42 -IL-4 CHO cells (0.8×10 6 ) were transiently transfected with 2 μg of the appropriate plasmid (pAβ 42 , pAβ 42 -IL-4, or pAβ 28 -IL-4) by Lipofectamine Plus Reagent (Invitrogen, Carlsbad, CA) and expressions of these plasmids were analyzed in the supernatants or lysates of cells. Cells transfected with vector were used as a negative control. All proteins were detected by combination of immunoprecipitation (IP) and WB using 6E10 anti-Aβ antibodies (Signet, MA). Tricine-SDS-polyacrylamide gel (16%, for Aβ 42 ) or 15% Tris-SDS-polyacrylamide gel (for fusion proteins) were used for electrophoresis. The antibody-antigen complexes were detected using horseradish peroxidase (HRP)-conjugated anti-mouse antibodies and Luminol reagent (Santa Cruz Biotechnology, Santa Cruz, CA).
Transfection of cells and expression of Aβ
Flow cytometry
The flow cytometry analysis was used for detection of Aβ 42 
Immunization
Immunizations of mice with experimental plasmids (two independent experiments with eight animals for each plasmid) were performed on shaved abdominal skin using the Helios gene gun (Bio-Rad, Hercules, CA) as we described [28] . Briefly, mice were bombarded two times with doses containing 1 μg of DNA per 0.5mg of ~1-μm gold beads (DeGussa-Huls Corp., Ridefield Park, NJ) at a helium pressure setting of 400 psi. Mice were immunized and boosted by the same method biweekly and sera were collected 7-8 days after the final boost. As a control we used animals (eight in each group) immunized by gene gun bombardment with psHA-mC3d 3 (positive), or with vector (negative) [28] .
ELISA
Total anti-Aβ 42 and anti-HA antibodies have been detected as described previously [7, 19, 28, 57] . Briefly, wells of 96-well plates (Immulon II; Dynatech) were coated with 2.5 μM of human or mouse Aβ 42 in bicarbonate coating buffer (pH 9.7) and incubated 3 h at 37°C or overnight at 4°C. They were then washed and blocked with 3% non-fat dry milk in Tween-20 Tris buffer solution (TTBS) for 1-2 h at 37°C. After washing of the wells primary sera from experimental and control mice were added in duplicate at the indicated dilutions. After incubation (O/N at 4°C) and washing, HRPconjugated anti-mouse IgG was added as recommended by manufacturer (Jackson Laboratories). Plates were incubated for 1 h at 37°C, washed, and freshly prepared OPD substrate solution (o-phenylendiamine in 0.05 M phosphatecitrate buffer, pH 5.0; Sigma) was added to develop reaction. All plates were analyzed spectrophotometrically at 405 nm. Anti-HA antibodies have been detected by ELISA exactly as we described earlier [28] . Anti-IL-4 antibodies were detected as described above except that plates were coated with 200 pg/ml recombinant mouse IL-4 (BD Phar-Mingen).
Antibody isotyping
To determine the specific isotypes, sera from individual mice were diluted 1:250 and tested in duplicate as described above. To detect mouse IgG1, IgG2b, or IgM isotypes, we used antimouse Ig-subclass-specific HRP-conjugated secondary antibodies (Zymed, San Francisco, CA). To detect mouse IgG2c (IgG2a b ) isotype, we used biotin-conjugated mouse anti-mouse IgG2a b (Igh-1b) monoclonal antibody (PharMingen, San Diego, CA), followed by incubation with HRP-conjugated streptavidin (Vector Laboratories, Burlingame, CA). For detection of IgE and IgA isotypes we used appropriate isotype-specific anti-mouse antibodies (Zymed).
Mapping of Aβ 42 antigenic determinants by competition ELISA
Previously, we have detected antigenic determinants in Aβ 42 peptide using a competition ELISA assay where the small overlapping peptides mixed with antisera compete with binding to the Aβ 42 -coated plates [19] . Briefly, plates were coated with Aβ 42 , washed, and blocked, as described above. Sera from immunized individual mice (diluted 1:250) were mixed with 2.5 μMof Aβ 42 peptide or small overlapping peptides spanning amino acids 1-15 (Aβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 42 and incubated 1 h at 37°C. The peptidetreated sera were added in duplicate to Aβ 42 -coated plates and antibody binding was analyzed by ELISA as described above. The percent of inhibition by small peptides and by control full-length peptide was calculated based on binding of sera without competing peptides to Aβ 42 as 100%.
Detection of Aβ plaques in human brain tissues
Sera from immunized mice were screened for an ability to bind to Aβ plaques in the human brain. Briefly, pooled sera were added to the serial 50-μm brain sections of formalinfixed frontal cortical tissue from a patient (an 80-year-old man with neuropathological and behavioral patterns typical for severe AD). Sections were pretreated with 90% formic acid, and exogenous peroxidase was quenched. Three different titers of mice antisera were tested (1:500, 1:750, and 1:1,000 dilutions). As a negative control, we used the same dilutions of pre-immune sera. As a positive control, monoclonal anti-human Aβ antibody 6E10 (dilution 1:1,500) was used to immunostain plaques in AD brain sections. Binding of antisera to the plaques was blocked by soluble Aβ 42 peptide in a concentration of 2.5 μM. Binding of antibodies to the brain sections was determined via VECTASTAIN Elite ABC Mouse IgG /DAB substrate biotin-avidin system (both kits from Vector Laboratories), according to manufacturer's recommendations. Digital camera (Olympus, Japan) was used to view the plaques at 20× image magnification.
Detection of neuroinflammation in mouse brains
Mice were sacrificed and brains were removed, fixed in 4% paraformaldehyde for 24 h at 4°C
, and subsequently cut in serial 50-μm-thick sections. Sections were pretreated with 0.3% H 2 O 2 for 30 min to eliminate endogenous peroxidase activity. The following primary antibodies were used after blocking of sections: CD54 (ICAM) (3E2), CD45 (30-F11), CD11b (M1/70), CD4 (GK1.5), CD8a (53-6.7) (all from BD PharMingen). All antibodies were optimally diluted in 0.1 M Tris, 0.1% Triton X-100 and 2% BSA as recommended by the manufacturer. Bound antibodies were detected using biotinylated anti-hamster (Vector Laboratories) or preabsorbed biotinylated anti-rat (Jackson Immunoresearch) antibodies followed by incubation with avidin:biotin peroxidase complex (ABC), using the Vectastain Elite kit (Vector Laboratories). Staining reactions were performed with 3,3-diaminobenzidine (DAB; Sigma) according to manufacturers' protocols. For negative control, the primary antibody was omitted from the diluent. Binding of immune (Aβ 42 -IL-4), pre-immune (negative control) sera, and 6E10 monoclonal antibody (positive control) to the 50-μm brain sections of formalin-fixed cortical tissues from an 80-year-old man with neuropathological and behavioral patterns typical to severe AD. Both pre-immune and immune sera were used at a dilution of 1:1,000, whereas the monoclonal antibody 6E10 was used at a dilution of 1:1,500. Binding of antisera to the brain tissue was blocked by Aβ 42 peptide. Arrows indicate senile plaques in frontal cortex sections. CD11b-positive microglial cells exhibited a resting morphology with long fine processes (illustrated in insets). CD4-positive cells were found within blood vessels (insets), but had not infiltrated into the neuropil. Bars = 50 mm. These data were repeated with two other animals.
